Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

计划入组 60 人 · 首次发布于 2025 年 7 月 31 日

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

计划入组 105 人 · 首次发布于 2025 年 4 月 29 日

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

计划入组 108 人 · 首次发布于 2024 年 2 月 8 日

STX

trimethylangelicin (Rare Partners)

STX-300s

Trillium Health Partners

Canada

New Leaf Partners

United States

Partners In Health

United States

Sharp Therapeutics Secures $10M Funding to Advance Gaucher Disease Treatment Toward Phase I Trials

STX-478 Shows Promise as Mutant-Selective PI3Kα Inhibitor in Solid Tumors

Eli Lilly Acquires Scorpion's Cancer Drug STX-478 in $2.5 Billion Deal